fluoxetine has been researched along with sibutramine in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (13.51) | 18.2507 |
| 2000's | 21 (56.76) | 29.6817 |
| 2010's | 11 (29.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ang, KK; Arkin, MR; Chen, S; Doyle, PS; Engel, JC; McKerrow, JH | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M | 1 |
| Heal, DJ; Hutchins, LJ; Jackson, HC; Mazurkiewicz, SE; Needham, AM | 1 |
| Auerbach, SB; Gundlah, C; Heal, DJ; Martin, KF | 1 |
| Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS | 1 |
| Connoley, IP; Frost, I; Heal, DJ; Liu, YL; Reckless, IP; Stock, MJ | 1 |
| Kalia, M; Kramer, M; Miller, DB; O'Callaghan, JP | 1 |
| Cheetham, SC; Heal, DJ; Slater, NA; Viggers, JA | 1 |
| Deslandes, PN; Pache, DM; Sewell, RD; Subhan, F | 1 |
| Czupryniak, L; Drzewoski, J | 1 |
| Sanders, TA; Taylor, D; Werneke, U | 1 |
| Jones, SL; Miller, DK; Wellman, PJ | 1 |
| Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X | 1 |
| Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W | 1 |
| Arterburn, D | 2 |
| Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X | 1 |
| Akdemir, O; Arslan, M; Karabacak, IY; Karabacak, O; Törüner, FB | 1 |
| Arterburn, D; DeLaet, D; Flum, D | 1 |
| Cesarino, EJ; de Almeida, CA; de Carvalho, D; Guimarães, C; Iucif Júnior, N; Pereira, LR; Queiroz, RH | 1 |
| Toubro, S | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Magaldi, AJ; Seguro, AC | 1 |
| Ciccocioppo, R; Cifani, C; Massi, M; Melotto, S; Polidori, C | 1 |
| Babbs, AJ; Chatfield, RE; Krülle, TM; McCormack, JG; Provost, D; Thomas, GH; Widdowson, PS | 1 |
| Ciccocioppo, R; Cifani, C; Di Francesco, C; Massi, M; Melotto, S; Righetti, C; Tessari, M; Zanoncelli, A | 1 |
| Kachowski, L; Over, DR; Qiu, K | 1 |
| Caricati-Neto, A; da Silva Júnior, ED; de Souza, BP; Drawanz Pereira, J; Ferreira Verde, L; Jurkiewicz, A; Jurkiewicz, NH; Mendes Sobrinho, C; Miranda-Ferreira, R; Soubhi Smaili, S | 1 |
| Humpston, CS; Robinson, ES; Wood, CM | 1 |
| Hirano, M; Nishimura, Y; Shimada, Y; Tanaka, T | 1 |
| Kang, D; Wang, X; Wu, T; Xu, L; Zhuang, J | 1 |
| Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H | 1 |
| Atkinson, G; Baur, L; Corpeleijn, E; Ells, LJ; Finer, N; Mead, E; Metzendorf, MI; O'Malley, C; Richter, B | 1 |
13 review(s) available for fluoxetine and sibutramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabolism; Fenfluramine; Fluoxetine; Humans; Obesity | 1997 |
Challenges in obesity management.
Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobutanes; Diethylpropion; Ephedrine; Fenfluramine; Fluoxetine; Humans; Lactones; Leptin; Lipase; Obesity; Orlistat; Phentermine; Proteins; Sertraline | 1998 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; Metformin; Nizatidine; Obesity; Orlistat; Topiramate; Weight Gain | 2002 |
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy; Female; Fluoxetine; Humans; Lactones; Male; Meta-Analysis as Topic; Middle Aged; Orlistat; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Loss | 2004 |
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate | 2004 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine | 2003 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine; Selective Serotonin Reuptake Inhibitors | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss | 2005 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine | 2005 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
Antidepressants for polycystic ovary syndrome.
Topics: Antidepressive Agents; Cyclobutanes; Depression; Female; Fluoxetine; Humans; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic | 2013 |
Drug interventions for the treatment of obesity in children and adolescents.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Cyclobutanes; Fluoxetine; Humans; Lactones; Metformin; Orlistat; Pediatric Obesity; Randomized Controlled Trials as Topic | 2016 |
3 trial(s) available for fluoxetine and sibutramine
| Article | Year |
|---|---|
Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease.
Topics: Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Female; Fluoxetine; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Leptin; Luteinizing Hormone; Polycystic Ovary Syndrome; Selective Serotonin Reuptake Inhibitors | 2004 |
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Appetite Depressants; Cholesterol; Combined Modality Therapy; Cyclobutanes; Fluoxetine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Placebos; Single-Blind Method | 2006 |
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Diethylpropion; Female; Fluoxetine; Follow-Up Studies; Humans; Mazindol; Obesity; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; Weight Loss | 2014 |
21 other study(ies) available for fluoxetine and sibutramine
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocytes; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Muscle, Skeletal; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptake Inhibitors; Obesity; Rats; Rats, Sprague-Dawley; Venlafaxine Hydrochloride | 1997 |
In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cyclobutanes; Fenfluramine; Fluoxetine; Male; Microdialysis; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin | 1997 |
Thermogenic effects of sibutramine and its metabolites.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Atenolol; Body Temperature; Body Temperature Regulation; Chlorisondamine; Cyclobutanes; Dose-Response Relationship, Drug; Female; Fluoxetine; Ganglionic Blockers; Glucose; Oxygen Consumption; Phenethylamines; Propanolamines; Rats; Rats, Wistar | 1999 |
Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Dexfenfluramine; Eating; Fluoxetine; Immunohistochemistry; Male; N-Methyl-3,4-methylenedioxyamphetamine; Prefrontal Cortex; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Sertraline | 2000 |
Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine.
Topics: Animals; Appetite Depressants; Brain; Cyclobutanes; Dexfenfluramine; Fluoxetine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2000 |
Do antidepressants affect motivation in conditioned place preference?
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Cocaine; Conditioning, Psychological; Cyclobutanes; Cyclohexanols; Dose-Response Relationship, Drug; Fluoxetine; Male; Motivation; Norepinephrine; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
[The role of pharmacotherapy for treatment of obesity in adults].
Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agonists; Ephedrine; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat | 2000 |
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Body Weight; Cyclobutanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Eating; Fenfluramine; Fluoxetine; Male; Norepinephrine; Phentermine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2003 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fluoxetine; Follow-Up Studies; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Risk Factors; Weight Loss | 2007 |
A possible mechanism for severe symptomatic hyponatremia during sibutramine therapy.
Topics: Animals; Appetite Depressants; Cyclobutanes; Fluoxetine; Humans; Hyponatremia; Rats; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2008 |
A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam.
Topics: Animals; Appetite Depressants; Behavior, Animal; Bulimia; Cyclobutanes; Disease Models, Animal; Eating; Feeding Behavior; Female; Fluoxetine; Food Deprivation; Fructose; Midazolam; Rats; Rats, Sprague-Dawley; Stress, Psychological; Topiramate | 2009 |
5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Appetite Depressants; Blood Pressure; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Fluoxetine; Heart Rate; Male; Models, Animal; Morpholines; Norepinephrine; Pyrimidines; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Triazines | 2009 |
Pre-exposure to environmental cues predictive of food availability elicits hypothalamic-pituitary-adrenal axis activation and increases operant responding for food in female rats.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Conditioning, Operant; Corticosterone; Cues; Cyclobutanes; Environment; Feeding Behavior; Female; Fluoxetine; Fructose; Humans; Hypothalamo-Hypophyseal System; Motivation; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rats; Reproducibility of Results; Rimonabant; Selective Serotonin Reuptake Inhibitors; Topiramate | 2009 |
FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus.
Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Fructose; Humans; Lactones; Orlistat; Selective Serotonin Reuptake Inhibitors; Topiramate | 2012 |
Changes of cytosolic calcium and contractility of young rat vas deferens by acute treatment with amphetamine, fluoxetine or sibutramine.
Topics: Amphetamine; Animals; Calcium; Central Nervous System Agents; Cyclobutanes; Cytosol; Fluoxetine; Homeostasis; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Rats; Rats, Wistar; Time Factors; Vas Deferens | 2012 |
Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Choice Behavior; Cyclobutanes; Cyclohexanols; Fluoxetine; Hypnotics and Sedatives; Idazoxan; Impulsive Behavior; Male; Norepinephrine; Paroxetine; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
A high-throughput fluorescence-based assay system for appetite-regulating gene and drug screening.
Topics: Animal Feed; Animals; Appetite Depressants; Appetite Regulation; Cyclobutanes; Drug Evaluation, Preclinical; Feeding Behavior; Fluorescent Dyes; Fluoxetine; Gene Expression Regulation; Gene Knockdown Techniques; High-Throughput Screening Assays; Humans; Larva; Paramecium; Zebrafish | 2012 |